The Therapeutic Effect of Thalidomide in Syringomyelia
About this trial
This trial is enrolling 30 participants with refractory syringomyelia to test the effect of thalidomide. Thalidomide is a drug with anti-inflammatory and immune modifying properties. If included, participants will receive 50–200 mg of thalidomide once at nightime. Final testing of sensory and motor scores will be performed after 3 months.
Included participants
What’s involved
Type
Details
- Participants will receive 50 – 200 mg of thalidomide once at nightime. - Thalidomide is a drug with anti-inflammatory and immunomodulatory properties. - Final testing of sensory and motor scores will be performed after 3 months.
Potential benefits
Main benefits
General health
Additional benefits
Arm/hand function
Pain
Sensory function
Standing/walking/mobility
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more- Trial recruitment status
- Recruiting
- Trial start date
- 1 Feb 2024
- Organisation
- Xuanwu Hospital, Beijing
- Trial recruitment status
- Recruiting
- Trial start date
- 1 Feb 2024
- Organisation
- Xuanwu Hospital, Beijing
About this trial
Included participants
What’s involved
Potential benefits
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more